scholarly journals Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early‐stage luminal breast cancer

2020 ◽  
Vol 77 (4) ◽  
pp. 579-587
Author(s):  
Julia E C Steenhoven ◽  
Anne Kuijer ◽  
Robert Kornegoor ◽  
Gijs Leeuwen ◽  
Joost Gorp ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mitotic Activity ◽  
Activity Index ◽  
Early Stage ◽  
Luminal Breast Cancer ◽  
Phosphohistone H3 ◽  
Mitotic Activity Index ◽  
Tumour Proliferation

Abstract P5-02-11: Assessment of tumor proliferation by mitotic activity index, phosphohistone H3 and Ki67 in early stage ER+/Her2- breast cancer

2020 ◽  
Author(s):  
Julia E.C. van Steenhoven ◽  
Anne Kuijer ◽  
A. M. van Leeuwen ◽  
Joost M. van Gorp ◽  
Paul J. van Diest ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mitotic Activity ◽  
Activity Index ◽  
Early Stage ◽  
Tumor Proliferation ◽  
Her2 Breast Cancer ◽  
Phosphohistone H3 ◽  
Mitotic Activity Index

scholarly journals The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e81902 ◽  
Author(s):  
Marie Klintman ◽  
Carina Strand ◽  
Cecilia Ahlin ◽  
Sanda Beglerbegovic ◽  
Marie-Louise Fjällskog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mitotic Activity ◽  
Prognostic Value ◽  
Activity Index ◽  
Cyclin A ◽  
Cyclin B1 ◽  
Premenopausal Breast Cancer ◽  
Node Negative ◽  
Phosphohistone H3 ◽  
Mitotic Activity Index

scholarly journals Comparing the Prognostic Value of PTEN and Akt Expression with the Mitotic Activity Index in Adjuvant Chemotherapy-Treated Node-Negative Breast Cancer patients aged <55 years

2007 ◽  
Vol 29 (1) ◽  
pp. 25-35
Author(s):  
Emiel A. M. Janssen ◽  
Håvard Søiland ◽  
Ivar Skaland ◽  
Einar Gudlaugson ◽  
Kjell H. Kjellevold ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Patients ◽  
Mitotic Activity ◽  
Invasive Breast Cancer ◽  
Prognostic Value ◽  
Activity Index ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Mitotic Activity Index

Background: The prognostic value of the PI3K/Akt/mTOR pathway and PTEN in invasive breast cancer (IBC) is controversial. Cell proliferation, especially the Mitotic Activity Index (MAI), is strongly prognostic in lymph node-negative (LNneg) invasive breast cancer. However, its prognostic value has not been compared with the value of Akt and PTEN expression. Material and Methods: Prognostic comparison of Her2Neu, p110alpha (PIK3CA), Akt, mTOR, PTEN, MAI and cell-cycle regulators in 125 LNneg patients aged <55 years with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-based adjuvant systemic chemotherapy. Results: Twenty-one (17%) patients developed distant metastases = DMs (median follow-up: 134 months). p110alpha correlated (p = 0.01) with pAkt but only in PTEN-negatives; pAkt correlated (p = 0.02) with mTOR. PTEN-negativity correlated with high MAI, high grade and ER-negativity (p = 0.009). The MAI was the strongest prognosticator (Hazard Ratio = HR = 2.9, p = 0.01). Her2Neu/p110α/Akt/mTOR features have no additional prognostic value to the MAI. PTEN had additional value but only in MAI < 3 (39/125 = 31%; 8% DMs). 19/39 = 49% of the MAI < 3 patients have combined MAI < 3 / PTEN+ with 0% DMs, contrasting 15% DMs in MAI < 3 / PTEN− (p = 0.03). Conclusions: In T1−3N0M0 adjuvant CMF-treated breast cancer patients aged <55 years, MAI was the strongest survival predictor. The PI3K/Akt/mTOR pathway and cell-cycle regulator characteristics had no additional prognostic value, but PTEN has. Patients with combined MAI < 3 & PTEN-positivity had 100% survival. The small subgroup of MAI < 3 patients that died were PTEN-negative.

scholarly journals In Patients Younger Than Age 55 Years With Lymph Node–Negative Breast Cancer, Proliferation by Mitotic Activity Index Is Prognostically Superior to Adjuvant!

2011 ◽  
Vol 29 (7) ◽  
pp. 852-858 ◽  
Author(s):  
Tone Hoel Lende ◽  
Emiel A.M. Janssen ◽  
Einar Gudlaugsson ◽  
Feja Voorhorst ◽  
Rune Smaaland ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Mitotic Activity ◽  
Systemic Therapy ◽  
Activity Index ◽  
Multivariable Analysis ◽  
Adjuvant Systemic Therapy ◽  
Cancer Proliferation ◽  
Cancer Specific Survival ◽  
Mitotic Activity Index

PurposeIn breast cancer, different tools are used for prognostication and adjuvant systemic therapy selection. We compared the accuracy of the online program Adjuvant!, the Norwegian Breast Cancer Group (NBCG) guidelines, and the proliferation factor mitotic activity index (MAI) in patients with lymph node (LN) –negative disease (pN0).Patients and MethodsAdjuvant! and MAI thresholds were set to 90% to 95% breast cancer–specific survival (BCSS) rates. These thresholds were 95% for Adjuvant!, 3 for MAI, and as follows for NBCG: pT1 grade 1 + pT1a-b grade 2 to 3; all pN0M0 and estrogen receptor/progesterone receptor positive versus all others. In 516 patients younger than age 55 years (T1-3N0M0) without adjuvant systemic therapy, univariable and multivariable 10-year BCSS rates were estimated.ResultsMedian follow-up time was 118 months. The concordance between MAI and Adjuvant! or NBCG was fair (κ = 0.35 and κ = 0.29, respectively). Adjuvant!, NBCG, and MAI were all prognostically significant (P ≤ .001). In the univariable analysis, the 10-year BCSS of MAI less than 3 versus ≥ 3 was 95% v 71%, respectively, with a hazard ratio of 7.0. In multivariable analysis, MAI was superior to Adjuvant! and NBCG. The 10-year survival of Adjuvant! ≥ 95% versus less than 95% was 91% v 74%, respectively, but stratification by MAI identified subgroups with different prognosis. Similar results occurred for NBCG and MAI. Adjuvant! and NBCG were not prognostic to each other.ConclusionMAI is superior to Adjuvant! and NBCG in prognostication of patients with LN-negative breast cancer younger than age 55 years.

PP-9-10 The prognostic significance of protein tyrosin kinase, ER, PR, and the mitotic activity index in 86 primary breast cancer patients

1996 ◽  
Vol 32 ◽  
pp. 57
Author(s):  
J. Bayrak ◽  
M.A. Blankenstein ◽  
A. Hennipman ◽  
G. Rijksen ◽  
Ch. Gimbrère ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mitotic Activity ◽  
Primary Breast Cancer ◽  
Activity Index ◽  
Prognostic Significance ◽  
Breast Cancer Patients ◽  
Mitotic Activity Index ◽  
Tyrosin Kinase

The Prognostic Value of the Mitotic Activity Index in Patients with Primary Breast Cancer Who were not Treated with Adjuvant Systemic Therapy

2003 ◽  
Vol 77 (1) ◽  
pp. 77-84 ◽  
Author(s):  
P. Manders ◽  
P. Bult ◽  
C.G.J. Sweep ◽  
V.C.G. Tjan-Heijnen ◽  
L.V.A.M. Beex
Keyword(s):  
Breast Cancer ◽  
Mitotic Activity ◽  
Systemic Therapy ◽  
Primary Breast Cancer ◽  
Prognostic Value ◽  
Activity Index ◽  
Adjuvant Systemic Therapy ◽  
Mitotic Activity Index

scholarly journals Comparison of diagnostic validity between mitotic activity index and Ki-67 expression as predictor for breast cancer in distant metastasis

2019 ◽  
Vol 7 (6) ◽  
pp. 2072
Author(s):  
Andreasta Ginting ◽  
I. Gede Budhi Setiawan ◽  
I. Wayan Sudarsa ◽  
I. Gede Raka Widiana
Keyword(s):  
Breast Cancer ◽  
Mitotic Activity ◽  
Distant Metastasis ◽  
Activity Index ◽  
P Value ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Diagnostic Characteristics ◽  
Significant Difference ◽  
Mitotic Activity Index

Background: One particular cause of death from breast cancer is distant metastasis. In this study, we calculate and compare  diagnostic value of Mitotic Activity Index (MAI) and Ki-67 expression in predicting distant metastasis.Methods: Study was conducted in Sanglah Hospital from January 2017 to February 2019. All histopathology results from open biopsy are examined, thus MAI and Ki-67 values were obtained. We divided this into 2 groups: MAI high (≥20/HPF), low (<20/HPF) and Ki-67 high (≥20%) and low (<20%). We compared with distant metastasis event as gold standard, obtained from radiology examination. We count all diagnostic characteristics (sensitivity, specificity, positive and negative predictive value, accuracy, and likelihood ratio). We compared these diagnostic validities from data area under curve (AUC) with p value <0.005 considered to be statistically significant.Results: A total of 173 breast cancer patients were participated in this study, 92 of them had distant metastasis (53.2%) and 81 patients didn’t have any distant metastasis (46.8%). MAI had relative high specificity (82.7%) and Ki-67 had fair sensitivity values (69.6%). There are 0.08 point AUC differences between these two variables. With p value higher than 0.05 (0.06), it can be summarized that these two variables are not different significantly and statistically.Conclusions: There is not any statistically significant difference between these two markers in predicting distant metastasis in breast cancer. We hope other researcher interest into exploring more about these markers and their function.

Sign in / Sign up

Export Citation Format

Share Document